Metabolite-Based Test Detects Pancreatic Cancer

This article originally appeared here.
Share this content:
Metabolite-Based Test May Detect Early Pancreatic Cancer
Metabolite-Based Test May Detect Early Pancreatic Cancer

(HealthDay News) -- A test that measures four serum metabolites can accurately distinguish patients with pancreatic cancer from healthy people and patients with pancreatitis, according to a study published online March 29 in Cancer Epidemiology, Biomarkers & Prevention.

Takashi Kobayashi, MD, PhD, from the Kobe University Graduate School of Medicine in Japan, and colleagues used gas chromatography-mass spectrometry to identify serum metabolites present in 43 patients with pancreatic cancer and 42 healthy volunteers.

The researchers found that a diagnostic model using four metabolites had a sensitivity of 86% and a specificity of 88.1%. Applying the model to an independent group of 42 patients with pancreatic cancer, 23 patients with chronic pancreatitis, and 41 healthy volunteers gave a sensitivity of 71.4% and a specificity of 78.1%. Compared with conventional tumor markers, the model had a higher sensitivity (77.8%) for resectable pancreatic cancer and a lower false positive rate (17.4%) for chronic pancreatitis.

"Our model possessed higher accuracy than conventional tumor markers at detecting the resectable patients with pancreatic cancer in [a] cohort including patients with chronic pancreatitis," the authors write.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs